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Introduction
Neuroinflammation and neurodegeneration both contribute to pathobiology of multiple sclerosis (MS). 1 The disease most often starts with active inflammation, whence the adaptive immune system attacks the central nervous system (CNS) and forms focal inflammatory lesions leading to demyelination. The pathological cascade soon develops to contain features of neurodegeneration with glial activation, axonal damage and tissue atrophy. 2 Activation of the innate immune system within the CNS (both resident microglia and blood-derived macrophages) contributes to neuronal damage via release of proinflammatory cytokines and reactive oxygen species which induce mitochondrial injury, and lead to oligodendrocyte damage and neurodegeneration. 3 Axonal loss underlies especially the transition from relapsing to progressive MS, but is known to be present already early in the disease. 3 At progressive stages of the disease, activated microglial cells are present both at the edge of chronic focal lesions (called chronic active lesions), and throughout the normal-appearing white matter (NAWM), which likely represent important background for the clinical disease progression. 3, 4 Conventional magnetic resonance imaging (MRI) is sensitive in demonstrating focal inflammatory lesions and gross atrophy and therefore forms the cornerstone of MS diagnostics and clinical follow-up today. MRI, however, fails to detect the diffuse pathology associated particularly with progressive MS. Positron emission topography (PET), on the other hand, provides a method to specifically quantitate microglial activation as an important manifestation of the diffuse pathology taking place outside the focal plaques in the NAWM. Thus, PET allows longitudinal follow-up of the above-described aspects of the progressive disease. In the future, PET might provide an important tool in attempts to develop treatments for this disease. PET studies on MS have focused on evaluating microglial activation using the 18-kDa translocator protein (TSPO) ligands and on developing ways to assess remyelination. 5 In this Topical Review, we describe the advances made in imaging microglial activation in the field of MS and discuss its challenges and future prospects. accurate in vivo quantitation of the target molecules. 6 PET uses short-lived radioactive isotopes, such as 18 F and 11 C, bound to ligands which interact with their respective targets. 6 After administration, the bound ligands enter the CNS and can be detected by a PET camera ( Figure 1 ). Challenges of MS PET lie within the lack of a suitable reference tissue in MS brain, the complex modelling demands and complicated and expensive technology including the need of an on-site cyclotron, due to the short half-lives of the tracers.
Imaging microglial activation by TSPO radioligands
Measuring microglial activation relies on TSPO radioligands. TSPO, earlier called the peripheral benzodiazepine receptor (PBR), is a protein structure expressed on the outer mitochondrial membrane of activated microglia, 7 and its upregulation is considered to be a sensitive 'real-time' marker of neuroinflammation and neuronal injury. Several functions have been attributed to TSPO, either directly or indirectly, including immunomodulation and regulation of cholesterol transport. 8 In the 'resting' or surveying microglia, TSPO is expressed at a low level, mainly in the grey matter (GM). In non-neoplastic CNS damage without blood brain barrier (BBB) breakdown, microglia are the main cell population expressing TSPO, but also other cells, such as macrophages, reactive astrocytes and vascular endothelial cells, can express TSPO. 9, 10 The prototypic TSPO radioligand, [ 11 C]PK11195, was first used in in vivo human MS study in 1997. 11 [ 11 C]PK11195 has high specificity for TSPO, but its short half-life and low signal-to-noise ratio hinder its use. The abundant radioligand binding to the vasculature and to the plasma proteins and the lack of a clear reference region require complicated modelling. 12 The so-called Super-PK methodology (supervised clustering of the reference region) has been successfully applied to several [ 11 C]PK11195 PET studies of MS. [13] [14] [15] Despite its shortcomings, [ 11 C] PK11195 has still been the most commonly used TSPO tracer in studies of MS. 16 However, over 80 second-generation TSPO ligands with higher affinity and specificity are presently at some stage of development. 7, [17] [18] [19] [20] 
TSPO PET findings according to MS pathology

TSPO PET findings relative to focal inflammatory lesions
There is a wide consensus that TSPO binding is increased in acute lesions, and most studies agree that chronic T1 black hole-type lesions have low TSPO binding. 11,23 T2 lesions have higher TSPO binding during relapse than during stable disease. 21 Neuropathology studies have identified subtypes of chronic (non-enhancing) T1 black hole-corresponding lesions that are particularly prevalent in progressive MS. These lesions can be of the chronic active, slowly expanding (smouldering) type, with macrophages and activated microglial cells at the plaque edge, or chronic inactive type, without active cells of the innate immunity at the plaque rim. 4 Importantly, PET can be used to differentiate the chronic active and chronic inactive plaques also in vivo, which is impossible by MRI. Among advanced secondary progressive multiple sclerosis (SPMS) patients, 57% of the plaques were of the chronic active type, with increased TSPO binding at the plaque edge demonstrating persisting inflammatory activity. 15, 30 MRI is clearly the first choice in the clinic for detecting focal inflammatory lesions in MS. However, the ability to detect activated microglial cells using TSPO PET takes MS imaging a step forward from MRI in terms of specificity. TSPO PET could thus complement MRI by providing more specific immunological characterization of the lesions. PET could be used longitudinally to evaluate the lesion development in patients in vivo. It could bring specificity to the evaluation of T2 lesions at any given time point by allowing detection of various T2 lesion types. Then, one could investigate how the different lesion types affect disease prognosis and eventually design individual therapy accordingly. 
TSPO PET of diffuse inflammation in progressive MS
With advancing disease, pathology in MS spreads outside the focal lesions, with increasing microglial activation and axonal damage in the NAWM and GM. 4 This diffuse, compartmentalized inflammation cannot be detected using conventional MRI, but with careful modelling, it can be quantified using TSPO PET. Importantly, studies of progressive MS have demonstrated an increase in TSPO uptake which appears to correlate to disease severity and patient age. In primary progressive multiple sclerosis (PPMS), TSPO PET studies are still mostly lacking, but SPMS studies have clearly demonstrated that [ 11 C]PK11195 binding in the NAWM is significantly increased in SPMS compared to healthy controls. 14, 15, 21, 22 In relapsing-remitting multiple sclerosis (RRMS), such increase is less pronounced. 14 However, when compared to controls, also clinically isolated syndrome (CIS) patients have higher TSPO binding in NAWM, which predicts the conversion to clinically definite MS. 25 In these studies, all focal inflammatory lesions have been carefully masked out, and the tissue of interest comprises areas appearing normal in MRI. Hence, in this application, TSPO PET provides truly complementary information to MRI. Figure 2 demonstrates TSPO imaging findings related to different types of lesions as well as to NAWM in an individual patient.
Attempts to measure therapeutic effects using longitudinal TSPO PET
Longitudinal studies using TSPO imaging are still scarce. Kreisl et al. 31 reported recently an increase in TSPO binding among patients with Alzheimer's disease over a period of 2.4 years. The only published longitudinal TSPO PET study evaluating microglial activation in MS is by Ratchford et al., 24 where RRMS patients were evaluated before and after 1 year of glatiramer acetate treatment. In this study, 1-year treatment with glatiramer acetate reduced TSPO binding significantly in both cortical GM and cerebral white matter (WM) when compared with cerebellum. The study by Sucksdorff et al. included serial PET imaging of MS patients and showed that 6 months' fingolimod treatment did not reduce microglial activation in the WM or GM (submitted). This was somewhat surprising given the earlier work demonstrating clear reduction in microglial activation after fingolimod treatment in an EAE rat model. 32 A longitudinal study to evaluate the alteration in microglial activation in untreated MS patients is still awaited. It would be interesting to evaluate at a patient level the rate of the increase in microglial activation in relation to clinical progression and other imaging parameters. This would also give excellent comparative data for longitudinal TSPO PET studies evaluating therapeutics in progressive disease. Table 1 lists all MS studies performed so far using TSPO imaging. 
Methodological challenges of TSPO imaging in MS
Until today, the methods for modelling [ 11 C] PK11195 imaging have varied greatly from study to study. For instance, in some of the earlier studies using [ 11 C]PK11195, cortical GM has been used as a reference region, whereas in others it was the main target of interest. 22, 23 The use of a clustered reference region has now established its position for estimation of specific ligand binding in clinical [ 11 C] PK11195 studies, and there is hope for better comparison between studies. [13] [14] [15] 25 Nonetheless, subtle differences between the studies may still arise from differences in image reconstruction protocols and PET scanner features, as well as from the different methods used for kinetic modelling and region of interest (ROI) acquisition, and for calculating the parametric images. Development of methods for coregistration of MRI and PET scans and motion correction of PET scans will help to exclude unwanted signal and to detect the specific signal. Due to the rather poor BBB permeability of [ 11 C]PK11195, special care should be taken when performing direct comparisons of ligand uptake in Gd-enhancing lesions versus in non-enhancing lesions, as the BBB breakdown may predispose to a greater concentration of free ligand in the adjacent areas and lead to misinterpretation of the results. 33 Despite some studies showing promise for the second-generation TSPO ligands, 19 the anticipation of improved image quality related to these ligands has not been delivered, but instead, significant issues have emerged that may limit the application of these tracers. 33 First, there is genetically determined variation in the binding affinity for second-generation TSPO tracers at a population level. This is attributed to TSPO gene polymorphism, resulting in high-, medium-and low-affinity binding. 34 Meaningful evaluation of the imaging results can, however, be obtained by using simple genetic testing to determine the binder status of an individual. Moreover, the higher affinity of the second-generation ligands disproportionally increases the signal from the TSPO in the vasculature compared with that of the tissue, which necessitates advanced post-imaging modelling. Following the abundant tracer binding to the vasculature, the use of tissue reference approaches is difficult, and there is a need for further development of the quantification of the specific microglia-associated TSPO signal. To overcome some of the problems, the [ 11 C]PBR28 schizophrenia study used the whole-brain normalization of the TSPO signal with correction for endothelial binding, 35 but further validation is necessary before wider application of this method. 36
Other targets for evaluating neuroinflammation in MS
Adenosine A2A receptors Using [ 11 C]TMSX PET, increased A2AR expression was demonstrated in the NAWM of SPMS patients. Importantly, this was associated with higher Expanded Disability Status Scale (EDSS) and increased brain tissue loss. 37, 38 In vitro studies demonstrate that inflammatory stimuli lead to upregulation of A2AR on microglial cells and subsequently alter their morphology and behaviour. 39 Thus, adenosine A2A receptor (A2AR) seems to be a potential alternative target molecule for in vivo imaging of microglial activation. 37 Other A2AR-binding tracers with more favourable imaging properties and specific binding have been developed and will hopefully soon be evaluated for their usefulness in imaging of neuroinflammation. 40 Importantly, findings from EAE experiments suggest that A2AR might play a role in controlling inflammation in MS. 41, 42 Other targets Several other promising targets that have not yet been utilized in MS imaging have emerged in the field of neuroinflammation imaging. Purinoreceptor P2X7 binds ATP and is expressed on activated microglia. Novel P2X7 antagonists have been developed and are promising candidates for PET tracers. 43 Numerous ligands have recently been developed and preclinically tested for cannabinoid receptor 2, which is expressed on activated microglia. 44 In addition, histamine 4, cyclo-oxygenase 2 receptors, matrix metalloproteinases 2 and 9, monoamine oxidase B and folate receptors are linked to many inflammatory and autoimmune diseases and appear as interesting future targets for PET of neuroinflammation. [45] [46] [47] [48] [49] [50] 
Prospects of MS PET in clinical use
Due to the technical requirements and the complex modelling, TSPO PET imaging will not likely be an imaging technique that would be widely available, but probably will continue being an investigative tool in specialized PET centres. With advancing methodology, standardization of modelling, availability of control cohorts and fluorinated ligands, it is, however, possible that in the future TSPO imaging could be performed also in imaging centres with no on-site cyclotrons. It could answer specific questions perhaps related to differential diagnostics (MS lesion or tumour) 51 or prognostic questions (risk of progression).
Conclusion
TSPO PET has potential for the evaluation of MS pathology in vivo in a specific and quantifiable way at a molecular level and thus gives added value over conventional MRI. Detection of various pathological determinants in MS brain using PET will enable better understanding of the disease pathogenesis, provide alternative methods to monitor disease progression, aid in characterization of disease phenotypes and improve therapy evaluation particularly in progressive MS. TSPO PET could be used as a predictive tool to identify patients most at risk of progression and as an important surrogate marker in therapeutic studies of progressive MS. PET has potential for measuring the effects of new disease-modifying drugs aimed at reducing neurodegeneration and neuroinflammation in a non-invasive and clinically translational manner. Thus, PET could be included in the clinical trials of progressive MS in the future. There are, however, still technical challenges, and it is of importance to harmonize and validate the methodology used in post-processing and modelling of the TSPO PET signal in order to be able to perform multi-centre studies with larger cohorts. Further work is needed to understand the significance of the TSPO ligand uptake in terms of microglial phenotype, proinflammatory or neuroprotective, and to develop new and better ligands, and ones that can distinguish between different microglial phenotypes. 
